KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Inventory (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Inventory readings, the most recent being $3.2 billion for Q1 2026.

  • On a quarterly basis, Inventory fell 2.19% to $3.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 billion, a 2.19% decrease, with the full-year FY2025 number at $3.2 billion, up 5.72% from a year prior.
  • Inventory hit $3.2 billion in Q1 2026 for Teva Pharmaceutical Industries, roughly flat from $3.2 billion in the prior quarter.
  • In the past five years, Inventory ranged from a high of $4.1 billion in Q1 2023 to a low of $3.0 billion in Q4 2024.
  • Median Inventory over the past 5 years was $3.9 billion (2024), compared with a mean of $3.7 billion.
  • Biggest five-year swings in Inventory: fell 25.22% in 2024 and later increased 5.72% in 2025.
  • Teva Pharmaceutical Industries' Inventory stood at $3.8 billion in 2022, then rose by 4.9% to $4.0 billion in 2023, then fell by 25.22% to $3.0 billion in 2024, then increased by 5.72% to $3.2 billion in 2025, then fell by 0.09% to $3.2 billion in 2026.
  • The last three reported values for Inventory were $3.2 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.3 billion (Q3 2025) per Business Quant data.